• Study on the Effectiveness and Safety of Tisagenlecleucel for Adults with Hard-to-Treat or Returning Follicular Lymphoma

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    Belgium France Germany Italy The Netherlands Norway +1

  • Comparison of Sotorasib versus Docetaxel in Previously Treated Non-Small Cell Lung Cancer Patients with KRAS p.

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    France Germany Greece Italy The Netherlands Poland +2

  • Study on the Safety and Tolerability of Epcoritamab with Drug Combination for Patients with B-cell Non-Hodgkin Lymphoma

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    Czechia Denmark France Germany Hungary The Netherlands +1

  • Study Comparing MK-2870 with Chemotherapy (Docetaxel or Pemetrexed) for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutations

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Czechia France Germany Greece Italy Poland +1

  • Study of Valemetostat Tosylate for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

    Not recruiting

    2 1 1
    Investigated Drugs:
    France Italy Spain

  • Study on the Safety and Effectiveness of Mezigdomide and Dexamethasone for Patients with Relapsed and Refractory Multiple Myeloma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Spain

  • Study of MK-7684A and Pembrolizumab for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Germany Italy The Netherlands Poland Spain

  • Study on the Safety of A24110He for Patients with Type 2 Diabetes and High Triglycerides

    Not recruiting

    2 1 1
    Investigated Diseases:
    Investigated Drugs:
    Sweden

  • Study Comparing Brentuximab Vedotin with Drug Combination for Treating Advanced Classical Hodgkin Lymphoma in Patients

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    Belgium Czechia Denmark France Hungary Italy +3

  • Study on the Safety and Tolerability of Abelacimab Compared to Rivaroxaban in Patients with Atrial Fibrillation

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    Czechia Hungary Poland

powered by